Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
409 people get RDY articles and Market Currents by email alert.
Get email alerts on RDY »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (Feb 14, 2013)
-
-
-
Mylan: Profit From The Generics Boom With This PharmaCris Frangold • Thu, Nov 8, 2012 -
-
Analyst Scott Power Finds The Upside In Biotech Down UnderLife Sciences Report • Thu, Nov 8, 2012 -
-
Business Wire (Oct 10, 2012)
-
Business Wire (Oct 8, 2012)
-
-
-
-
-
-
-
India Markets Friday Wrap-Up: Persistent Selling Mars Indian IndicesEquitymaster • Fri, Jul 20, 2012
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
Dr. Reddy's And Pfizer Finally Settle Lipitor DisputeZacks Investment Research • Thu, Sep 1, 2011 -
-
-
-
-
-
-
-
Dr. Reddy's Posts Big Earnings Beat on Nausea Treatment SalesSA Editor Eli Hoffmann • Fri, May 18, 2007 -
Dr. Reddy's Launches Generic ZofranAaron F. Barkoff • Wed, Jan 24, 2007 -
Indian Market Report: Dr. Reddy's Moving Up QuietlyDinesh Pandya • Mon, Dec 25, 2006
-
Reddy's is Ready for Aggressive GrowthHari Vepadharmalingam • Tue, Sep 5, 2006 -
Indian Pharma Companies: No Respite Yet (RDY, RBXLF)Wisdomsmith • Wed, Jan 25, 2006
-
-
-
-
Mylan: Profit From The Generics Boom With This PharmaCris Frangold • Thu, Nov 8, 2012
-
-
Analyst Scott Power Finds The Upside In Biotech Down UnderLife Sciences Report • Thu, Nov 8, 2012
-
-
-
-
-
-
-
India Markets Friday Wrap-Up: Persistent Selling Mars Indian IndicesEquitymaster • Fri, Jul 20, 2012
-
India Markets Wednesday Wrap-Up: Late Buying Fuels Indian IndicesEquitymaster • Wed, Jul 18, 2012
-
India Markets Monday Wrap-Up: Global Signals Lead To Sell-OffEquitymaster • Mon, Jul 9, 2012
-
-
High Flying Indian ADRs: Play A Turnaround In IndiaQineqt • Mon, Jul 2, 2012 -
India Markets Monday Wrap-Up: Volatility Plagues Indian IndicesEquitymaster • Mon, Jul 2, 2012
-
India Markets Monday Wrap-Up: Persistent Selling Mars IndicesEquitymaster • Mon, Jun 18, 2012
-
Dr. Reddy's And Merck Serono Partner On BiosimilarsThe Burrill Report • Sun, Jun 10, 2012
-
at CNBC.com (Tue, 9:11AM)
-
Business Wire (Feb 14, 2013)
-
Business Wire (Oct 10, 2012)
-
at CNBC.com (Oct 8, 2012)
-
Business Wire (Oct 8, 2012)
-
at MarketWatch.com (May 18, 2012)
-
Business Wire (Apr 19, 2012)
-
Business Wire (Jan 16, 2012)
-
at MarketWatch.com (Jul 15, 2011)
-
at MarketWatch.com (Mar 10, 2011)
-
at CNBC.com (Feb 17, 2011)
-
at CNBC.com (Feb 1, 2011)
-
at MarketWatch.com (Jan 19, 2011)
-
at CNBC.com (Jan 11, 2011)
-
at MarketWatch.com (Dec 22, 2010)
-
at MarketWatch.com (Nov 18, 2010)
-
at CNBC.com (Nov 8, 2010)
-
at MarketWatch.com (Jun 15, 2010)
RDY vs. ETF Alternatives
Company Description
Dr. Reddy’s Laboratories Limited (“DRL” or the “parent company”), together with its subsidiaries (collectively, the “Company”), is a leading India-based pharmaceutical company headquartered in Hyderabad, Andhra Pradesh, India. The Company’s principal areas of operation are in pharmaceutical... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, March 22, 4:20 PM Dr. Reddy's Laboratories (RDY -1.1%) announces that it's settled claims against Nordion (NDZ +0.1%) by accepting a cash payment of $22.5M. The case was brought by RDY in April 2009 seeking damages caused by a purported breach by NDZ of its Laboratory Services Agreement with the company. 1 Comment [Global & FX, Healthcare]
- Monday, February 25, 4:39 PM Transcept Pharmaceuticals (TSPT) says that on February 21 it received a new Paragraph IV notice letter from Dr. Reddy's Laboratories (RDY) advising that it's filed an Abbreviated New Drug Application with the FDA for generic versions of Intermezzo. Comment! [Healthcare]
- Friday, September 28, 2012, 11:47 AM A U.S. appeals court upholds a lower court ruling in favor of Pozen (POZN -0.8%) against Par Pharmaceutical (PRX), Alphapharm and Dr. Reddy’s Laboratories (RDY +1.9%), affirming the district court's earlier decision that found POZN's patent valid, and blocked PRX and RDY from selling a generic version of POZN's migraine drug Treximet until 2025. Comment! [Healthcare]
- Friday, July 27, 2012, 11:14 AM The USFDA has lifted an import alert it had placed on Dr. Reddy Laboratories (RDY -0.6%) at its chemical manufacturing facility in Cuernavaca, Mexico. The Mexico facility was inspected by the agency in November 2010, and based on observations, a Warning Letter was shared with the company on June 14, 2011. Now, with the satisfactory closure of observations in the warning Letter and the lifting of the import alert, Dr. Reddy's is free to once again import products to the US from this facility. Comment! [Global & FX, Healthcare]
- Friday, May 11, 2012, 7:28 AM Dr. Reddy's Laboratories (RDY): FQ4 EPS of $0.40 in-line. Revenue of $522M (+32% Y/Y) beats by $126M. (PR) Comment! [Earnings, Healthcare]
- Thursday, January 5, 2012, 2:24 PM Morgan Stanley names Dr. Reddy's Labs (RDY -0.9%) a Long Research Tactical Idea with an eye on the firm's plans to launch a generic version of Lipitor later this year. Comment! [Healthcare, Quick Ideas]
- Thursday, November 3, 2011, 5:44 PM Seeking Alpha offers dueling lists of dividend stocks, naming 10 that look expensive - PM, LTD, CL, LLTC, HSY, MO, HLF, YUM, COH, ACN - and another 10 that appear undervalued - RDY, LFUS, ISCA, DOW, WYNN, COF, BG, TSU, HFC, ALEX. 2 Comments [Quick Ideas]
- Monday, October 24, 2011, 3:46 PM The FDA approves the first generic versions of Zyprexa tablets and Zyprexa Zydus orally disintegrating tablets to treat schizophrenia and bipolar disorder. The drugs will be jointly manufactured and distributed by Dr. Reddy's Labs (RDY +1%), Teva Pharmaceuticals (TEVA +0.9%) and Par Pharmaceuticals (PRX +1.9%). Comment! [Healthcare]
- Monday, October 25, 2010, 3:55 PM India's stock market has jumped 19% so far this year, and its economy is forecast to rank in the top three of the world's largest economies by 2040. One analyst's top three stock picks among Indian firms: Dr. Reddy's Laboratories (RDY +1.6%), ICICI Bank (IBN +0.7%) and Infosys (INFY -0.7%). 2 Comments
- Tuesday, June 16, 2009, 7:38 AM GlaxoSmithKline (GSK) teams up with Indian drug maker Dr. Reddy's Laboratories (RDY) to focus on emerging markets, excluding India. For Glaxo, this is just the latest in a series of moves designed to expand the company's emerging markets presence. Comment!
- Monday, May 18, 2009, 8:05 AM Dr. Reddy's Laboratories (RDY): FQ4 net profit of INR1.56 billion vs. consensus of INR 1.17B. Revenue of INR16.78B. Shares +10.6% premarket. (DJ) Comment!
- Monday, May 18, 2009, 12:05 AM Notable earnings before Monday's open: LOW, PWRD, RDY 1 Comment
- Tuesday, January 20, 2009, 8:14 AM Dr Reddy's Laboratories (RDY): FQ3 net profit of 1.92B rupees ($39M) vs. net loss of 1.21B rupees a year ago. RDY missed profit consensus of 2.01B rupees, mostly due to lower earnings in Europe. Comment!
- Thursday, October 23, 2008, 6:26 AM Drugmaker Dr. Reddy's (RDY) reports FQ2 net profit -22% Y/Y, worse than analyst expectations, and did not give a reason for the fall in profit. Shares -9% in Frankfurt. Comment!
- Monday, July 21, 2008, 7:13 AM Dr. Reddy's (RDY): FQ1 net income fell 26%, beating consensus. Revenue rose 26%. [PR] Comment!
- Monday, July 21, 2008, 12:03 AM Notable earnings after Monday's close: AAPL, AMLN, AXP, BSX, CNI, CX, EXP, EFX, FNB, HPC, LNCR, LOGI, LRY, MHK, MRK MTW, PKG, QLGC, RDY, SGP, RE, SNDK, SSCC, STLD, TCK, TXN, VLTR, WBSN, ZRAN Comment!
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.